U.S. drug maker Merck is building a $1 billion facility in Wilmington, Delaware, aimed at increasing domestic production of ...

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

Merck estimates the project will create more than 500 full-time roles and about 4,000 construction jobs. CEO of Main Line ...

The drug maker on Tuesday announced a new 470,000-square-foot facility in Wilmington, Delaware, where it will make Keytruda, ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Merck is expanding domestic manufacturing with a $895 million investment in its Kansas factory, one of several major projects ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

Merck & Co (MSD) has begun construction on a $1bn biologics centre of excellence, Merck Wilmington Biotech, in Delaware, US.

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...